Clinical Trials Browser

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type

NCT05139706 2026-02-03

MIRAE

Recruiting

1,000 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Autoimmune Diseases, Immune System Diseases, Inflammation, Neoplasms

NCT02690545 2026-01-06

Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

Phase 1/2 Active not recruiting

38 enrolled

Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type

NCT03602157 2026-01-06

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Phase 1 Active not recruiting

43 enrolled

DermatologicLymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Mycosis Fungoides, Neoplasms, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis

NCT03696784 2025-12-08

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

Phase 1 Active not recruiting

19 enrolled

Lymphoid

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, B-Cell, Neurotoxicity Syndromes

NCT04830046 2025-11-26

Covid-19 Vaccine Responsiveness in MM and Waldenstrom

Completed

146 enrolled

LymphoidPlasma cell

COVID-19, Immune System Diseases, Waldenstrom Macroglobulinemia, Multiple Myeloma

NCT03016377 2025-10-27

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

Phase 1/2 Active not recruiting

17 enrolled

LymphoidOther hematologic neoplasm

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04656873 2025-09-04

IOG

Active not recruiting

32 enrolled

Autoimmune Diseases, Immune System Diseases, Neoplasms

NCT03207854 2025-07-11

Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers

Recruiting

500 enrolled

Other hematologic neoplasm

Hematologic Diseases, Immune System Diseases, Neoplasms, Hematologic Neoplasms

NCT05963217 2025-07-02

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

Phase 1 Recruiting

19 enrolled

LymphoidOther hematologic neoplasm

Immune System Diseases, Lymphoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Experimental, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05969821 2025-06-12

CHIS

Not yet recruiting

1,000 enrolled

LymphoidMyeloidOther hematologic neoplasm

VEXAS syndrome, Autoimmune Diseases, Hematologic Diseases, Immune System Diseases, Inflammation, Leukemia, Lymphoma, Lymphoproliferative Disorders, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Juvenile, Myelodysplastic-Myeloproliferative Diseases

NCT02663297 2025-05-15

Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

Phase 1 Active not recruiting

18 enrolled 10 charts

Lymphoid

Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type

NCT04658303 2025-05-08

Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma

Recruiting

20 enrolled

Dermatologic

Immune System Diseases, Melanoma

Clinical Trials

LEO

MIRAE

Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

Covid-19 Vaccine Responsiveness in MM and Waldenstrom

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

IOG

Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

CHIS

Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma